Comparative Pharmacology
Head-to-head clinical analysis: JANUVIA versus METFORMIN HYDROCHLORIDE AND SITAGLIPTIN PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JANUVIA versus METFORMIN HYDROCHLORIDE AND SITAGLIPTIN PHOSPHATE.
JANUVIA vs METFORMIN HYDROCHLORIDE AND SITAGLIPTIN PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing levels of active incretin hormones (GLP-1, GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon release.
Metformin: Activates AMP-activated protein kinase (AMPK), reducing hepatic glucose production, decreasing intestinal glucose absorption, and improving insulin sensitivity. Sitagliptin: Inhibits dipeptidyl peptidase-4 (DPP-4), increasing incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon release.
100 mg orally once daily
Oral, 50 mg sitagliptin/500 mg metformin twice daily with meals. Maximum: 100 mg sitagliptin/2000 mg metformin per day in divided doses.
None Documented
None Documented
Terminal elimination half-life: 12.4 hours. Clinical context: supports once-daily dosing in patients with normal renal function.
Metformin terminal half-life ~6.2 hours (prolonged in renal impairment; clinical context: dosing adjustment required if eGFR <45 mL/min). Sitagliptin terminal half-life ~12.4 hours (extended in renal impairment; dose adjustment for CrCl <50 mL/min).
Renal: approximately 87% (79% unchanged sitagliptin, 16% metabolites). Fecal/biliary: 13% (metabolites and unchanged drug).
Metformin is excreted unchanged in urine (90% renal tubular secretion) and feces (10%). Sitagliptin is excreted primarily unchanged in urine (87% renal, 13% fecal via biliary).
Category C
Category A/B
DPP-4 Inhibitor
DPP-4 Inhibitor